Pathological Microscopes Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario

The growth of the healthcare sector in conjunction with the rising prevalence of diseases is expected to create demand for advanced equipment over the next couple of years. A study conducted by Market Research Future (MRFR) on the pathological microscopes market projects that a CAGR of 4.50% over the assessment period 2018 to 2023. The report further underlines that the market is expected to scale a valuation of USD 523.20 Mn towards the close of 2023.

The increasing burden of diseases such as cancer, diabetes, tuberculosis, etc. is anticipated to intensify the demand for pathological equipment that facilitates early detection and diagnosis. It is projected to pave the way for innovation and development of devices that offer accuracy. This, in turn, is anticipated to have a favorable impact on the growth pattern of the pathological microscopes market in the years to come.

The automation drive witnessed in the laboratories is also projected to accelerate revenue creation for market participants. Again, the increasing count of laboratories and pathology labs are expected to propel the expansion of the pathological microscopes market over the next few years.

Competitive Analysis

Microscope manufacturers in the pathological microscopes market include Nikon Corporation (Japan), Leica Biosystems Nussloch GmbH (Germany), Olympus Corporation (Japan), ZEISS International (Germany), Labomed, Inc. (U.S.), Hitachi High-Technologies Corporation (Japan), Euromex Microscopen BV (The Netherlands), Bruker Corporation (U.S.), Sakura Finetek USA, Inc. (U.S.), and Celestron LLC (U.S.).

The players are focusing on integrating new technologies to expedite the diagnosis rate associated with microscopes and lower the mortality rate. Collaborations, new product launches, and partnerships are strategies being adopted to gain a larger market share.

Segmentation

The pathological microscopes market is segmented by type, application, and end-user.

By type, electron microscope held close to 41.4% share in 2017, followed by optical microscope (18.8%), compound microscope (13.5%), digital microscope (5.4%), fluorescence microscope (4.4%), and others (16.5%). Electron microscopes can generate nearly USD 217.81 million by 2023 owing to their application in life sciences. Prevalence of diseases such as anemia and leukemia which require the need of electron microscopes lend credence to the segment valuation. But digital microscopes can exhibit the highest CAGR of 5.01% during the forecast period to accumulate USD 28.90 million for the pathological microscopes market by 2023.

By end-user, pathology & diagnostic laboratories accounted for 45.2% market share in 2017, followed by hospitals & clinics (38.6%), forensic laboratories (11.5%), and others (4.7%). Hospitals & clinics will be the biggest end-user of the pathological microscopes market by 2023. It can generate USD 206.25 million by the end of the forecast period owing to the setup of various branches of hospital chains to handle high patient volume. On the other hand, pathology & diagnostic laboratories can generate USD 239.73 million by 2023 thanks to possessing various skilled personnel and use of hematology, clinical microbiology, and molecular pathology for rapid diagnosis of diseases.

By application, bodily fluids accounted for 79.4% share of the pathological microscopes market in 2017, followed by tissue scanning (12.7%), and others (7.9%). Bodily fluids can generate USD 418.84 million for the pathological microscopes market by 2023. This can be attributed to use of fluid samples to identify the presence of diseases such as tuberculosis in the human body. High prevalence of blood disorders is driving the segment growth. On the other hand, tissue scanning is touted to accumulate USD 67.94 million by 2023. High prevalence of cancer and use of digital microscopes to detect abnormal tissue growth can fuel the segment growth.

Regional Analysis

The global pathological microscopes market, by region, has been segmented into Americas, Europe, Asia Pacific, and the Middle East & Africa (MEA). Americas is expected to gain control over the maximum market share during the review period. The regional market is projected to touch a valuation of USD 190.98 Mn by the end of 2023. The advancements of laboratories being observed in the region are expected to drive the growth of the pathological microscopes market in the nearby future.

Asia Pacific is projected to exhibit healthy growth owing to the rapid developments in the healthcare sector. The pathological microscopes market in the region is anticipated to attract massive investments over the next couple of years, thus, augmenting the market.

Industry News:

In March 2019, Nikon Instruments Inc., a leader in advanced optical instruments, has announced a partnership with OptraSCAN, On-Demand Digital Pathology Solution Provider, for the launch of OS-15-N, a digital slide scanning system that features Nikon optics.

In January 2019, Roche, a Swiss multinational healthcare company, has announced the introduction of its uPath enterprise software for digital pathology.

Microbiology Testing Market Value Share, Supply Demand, Share And Value Chain 2019

Global Microbiology Testing Market - Overview

Microbiology testing has emerged as one of the rapidly changing and growing segment of healthcare over the past few years. Microbiology testing deals with the study of microbial germs and their clinical applications for the improvement of health. Microbiology testing is concern with the diagnosis, prevention and treatment of various infectious diseases such as, sexually respiratory infections, urinary tract infections, gastrointestinal infections, sexually transmitted infections, and many others. These diseases can be spread from one person to another, directly or indirectly.

According to a recent study published by the Market Research Future analysts, the global microbiology testing market is growing at a double digit growth rate; mainly due to factors such as technological advancements, rising cases of infectious diseases, surveillance programs for disease control, and rising stringency of standards.  On the other hand, erroneous results produced during the testing, and heavy costs of the tests and instruments have created some obstacles in the growth of this market in all parts of the world.

Global Microbiology Testing Market - Competitive Analysis

There are large number of companies involved in the development of the products, instruments, and test kits for the microbiology testing which are now being used in majority part of the developed countries. Global market for microbiology testing is majorly dominated by Biomérieux SA with more than 40% of market share in 2016.

Major companies are adopting a specific strategy to enter and create unique space in this market. The different strategies includes, product launch, agreement and collaboration, partnership and expansion, joint venture and strategic alliance etc. All major players are focusing on new product development to provide new and innovative solutions to the market.

Biomérieux SA offers a comprehensive range diagnostic solutions which include Microbiology lab instruments, reagents and software. The products of the company is mainly used for diagnosing infectious diseases. In 2016, BioMérieux announced the acquisition of Hyglos. With this acquisition, the company plans to strengthen its position in the market.

Some of the major developments in this segment came from the Roche Diagnostics. In April 2017, the company received FDA clearance for the CINtec Histology test. This test is the only clinically validated p16 biomarker test. The CINtec Histology test will help physicians make informed decisions as to the best course of care for patients with high-grade pre-cancerous cervical disease. Back in 2015, Roche acquired GeneWEAVE to strengthen offerings in microbiology diagnostics.

The global market consist of players such as Alere (US), BD (US), Beckman Coulter, Inc. (US), Biomérieux SA (France), Cepheid (US), F. Hoffmann-La Roche Ltd (Switzerland), and Thermo Fisher Scientific Inc. (US). These are the prominent players at the forefront of competition in the global microbiology testing market and are profiled in MRFR Analysis report.

Global Microbiology Testing Market - Regional Analysis

In 2016, North America and Europe were holding more than half market share of global microbiology testing market. Increasing funding for R&D is major driving force for the market growth. The funding for microbiology testing in US is one of the highest as compared to other countries. Rapid adoption of advanced products and techniques are driving the growth for North America market. Increasing cases of infectious diseases are promoting the research related activities in this region. Independent laboratories are dominating the North America market by adopting new technologies and trends.

European market is second highest revenue generator after North America. Europe microbiology testing market has benefited by the presence of some major players in this region. Moreover, increasing innovation and changing laboratory practices are driving the growth for Europe microbiology testing market. Microbiology testing have huge and increasing demand not only in developed countries but also in developing countries like China, India, and Spain.

Rising prevalence of respiratory infections are increasing burden on Asia-Pacific healthcare system. Being a large population base, increasing aging population, and increasing use of technology in healthcare, China microbiology testing market is growing at rapid pace. China is expected to grow at a CAGR of 12.8% during the forecast period. The number of independent laboratories are rapidly increasing such as KingMed Diagnostics and Dian Diagnostics. KingMed Diagnostics is largest chain of independent laboratories in china.

The Middle East and Africa microbiology testing market is growing dramatically due increasing prevalence of various infectious diseases like Ebola. This region is carrying greatest burden of infectious disease. Sexually transmitted diseases are also major public health problem in this region. There are some factors are affecting the microbiology testing market in this region such as, limited access to the healthcare facilities, lack of knowledge of new microbiology testing techniques, less funding R&D, limited availability of products etc.

Current And Forthcoming Dental Consumables Market Size In Terms Of Volume And Value 2019

Market Scenario:

Acknowledging the developments and accruals the market is enjoying currently, Market Research Future (MRFR) in its recently published study report asserts that the global dental consumables market will be valued at USD 28,345 MN by 2024, registering approximately 7 % CAGR during the forecast period (2016 – 2024). 

The global market of dental consumables, including US dental consumables market is growing pervasively mainly due to the technological advancements that took place in the dental industry. Although the integration of technology & consumables in dental practices goes back to decades, the uptake of consumables has been increasing over the past few years, and so is increasing the growth of the dental consumables market. Furthermore, factors such as the wide adoption of dental consumables along with the increasing geriatric populace, prevailing dental disorders and surgeries are driving the market growth.

The growing spread of the dentistry field has been a massive driver for the global dental consumables market over the forecast period. The field of dentistry has evolved rapidly in modern times to encompass several specialties such as orthodontics, prosthodontics, and endodontics. This has led to a growing demand for a number of procedures in the dentistry field as well as for the consumables used in these procedures. The rapid evolution of the dentistry field is likely to remain a major driver for the global dental consumables market over the forecast period. The growing insistence on single-use consumables, in order to ensure the sterility and safety of the component in each procedure, is also likely to drive the demand from the dental consumables market over the forecast period. While the field of dentistry has grown to encompass several sub-specialties, the instruments and equipment used by the various fields are largely similar, leading to a steady growth in demand from the dental consumables market.

The growing demand for dental procedures due to the growing prevalence of conditions such as plaque and dental caries is likely to remain a major driver for the global dental consumables market over the forecast period. Growing consumption of chocolate and candy among the younger generation has led to a growing prevalence of dental problems around the world, leading to a growing demand for dental procedures and thus for dental consumables. The growing disposable income of consumers in emerging regions is also likely to be a key driver for the global dental consumables market over the forecast period.

On the other hand, these dental consumables are costlier especially in developing and underdeveloped nations which in turn, is hampering the market growth in these regions restricting the uptake of consumables. Also, the operational complexities of these consumables may restrain the growth of this market.

Competitive Analysis:

Leading players in the global dental consumables market include Septodont, Straumann, KERR Corporation, EnvisionTEC, American Orthodontics, Dentsply Sirona, Nobel Biocare, Planmeca OY, Patterson Dental, GC Orthodontics, Henry Schein, and 3M.

In March 2019, the NHS announced a planned price increase for dental procedures from April 1. The price increase covers minor dental procedures as well as major operations such as root canal. This could have a key impact on the dental consumables market in Europe over the forecast period.

Segmentation:

The global dental consumables market is segmented on the basis of type and region.

By type, the global dental consumables market is segmented into dental implants, dental restorative materials, dental prosthetics, dental regenerative materials, and others. The dental implants segment is likely to remain the top earner in the global dental consumables market over the forecast period due to the growing demand for dental implants for health as well as cosmetic reasons.

Regional Analysis:

The global dental consumables market is segmented by region into Americas, Europe, Asia Pacific, and the Middle East and Africa.

Europe holds the largest share in the global dental consumables market by region and is likely to remain the leading revenue generator in the market over the forecast period due to the growing demand for advanced dental procedures in the region and the widespread availability of dental healthcare facilities. The growing scope of the healthcare sector in the region is likely to enable smooth growth of the dental consumables market over the forecast period.

Asia Pacific is likely to exhibit the fastest growth in the global dental consumables market over the forecast period due to the growing disposable income of consumers in the region and the growing prevalence of dental conditions requiring complicated operations and surgical procedures.

The Americas is also likely to hold on to a major share in the global dental consumables market due to the strong presence of several leading players in the dental consumables industry and the high spending power of the geriatric demographic in the region, which plays a key role in the growth of dental services and equipment.

Clear Aligners Market In Depth Study And Analysis Published, 2019

Market Snapshot

Clear Aligners market is anticipated to expand at a CAGR of 20.80% in the duration of the forecast period. Market Research Future presents Clear Aligners Industry future scope with Information by Product Type (Hard, Medium and Soft), Age (Adult and Teenager), Distribution Channel (Direct Sales and Laboratories) and Regional Analysis, Forecast till 2025

The increasing level of acceptance and demand for clear aligners is amplifying the expansion of the market steadily. The benefits of clear aligners are multiplying the number of individuals who are opting for it. This is primarily due to the improving number of individuals electing for cosmetic dental procedures since the past few years. The clear aligners market is expected to progress at a 20.80% CAGR while earning revenues worth USD 3982.30 Million in the duration of the forecast period. The evolution in terms of technology such as 3D printing, dental CAD software, and thermoforming machines is projected to transform the market favorably in the coming years.

Rapid technological advancement is aiding the evolution of dentistry with the development of advanced dental devices. Rise in prevalence of dental diseases and increase in geriatric population all over the world are inducing high demand for advanced dental devices which is leading to the significant growth of the global clear aligners market. High healthcare expenditure in developed and developing regions and increasing popularity of aesthetic dentistry among young population have created multiple opportunities for the expansion of the global clear aligners market. However, the treatment time required for clear aligners is comparatively higher than other procedures. Hence, the high treatment time, availability of cheaper products and lack of awareness among the population of underdeveloped areas are posing as a threat to the growth of the global clear aligners market.

Competitive Dashboard:

Globally, a large number of companies are working in the development and production of clear aligners. These major companies have adopted extensive research, in order to offer better and cost-effective products. The American and European regions are a hub for major companies, generating maximum market share which has turned these regions into a well-established market. These companies have expanded their operating units in various other regions as well. Moreover, there are various other small and medium scale players that generate revenue from the local market.

Some key players operating in this market are

• Align Technology, Inc.,
• Institut Straumann AG,
• Danaher Corporation,
• Dentsply Sirona,
• Clarus,
• 3M, among others.

Segmentation:

The global clear aligners market has been segmented into product type, age, distribution channel, and region.

Based on product type, the global market has been segmented into hard, medium, and soft.

Based on age, the global market has been divided into teenager and adult. The teenager segment is likely to hold the maximum share in the global market with a value of 1427.98 million in 2018.

Based on distribution channel, the global market has been divided into direct sales and distributor.

The global clear aligners market, based on region, is segmented into– the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is expected to command the largest market share due to aesthetic dentistry and other vast specialized services present in countries of North America. Additionally, the rising health expenditure per person and increasing demand for advanced technologies are driving the growth of the clear aligners market in these countries. Additionally, the presence of a large number of noticeable players in this region is the major driving factor of the market in the Americas.

Europe accounts for the second-largest market, majorly due to the soaring demand for dental procedures. Additionally, the increasing incidences of oral problems, vast application of technologically advanced techniques, and the growing importance of treatment, planning, and diagnosis in implant dentistry in European countries are driving the clear aligners market in Europe.

Asia-Pacific with lots of opportunities and continuously growing economies is expected to be the fastest-growing region. Furthermore, recent developments in healthcare and improving economies and disposable income per individual are fueling market growth.

The Middle East & Africa is expected to grow significantly during the forecast period due to the increasing cases of dental abnormalities and the demand for better teeth-related treatments in the region.

Gestational Trophoblastic Disease Market Revenue, Opportunity, Forecast And Value Chain Analysis 2019

Market Scenario:

Gestational trophoblastic disease (GTD) is a cluster of rare tumors that include abnormal growth of cells inside a woman's uterus. It arises from placental trophoblastic tissue and is characterized by β-subunit of human chorionic gonadotrophin (β HCG). The increasing prevalence of risk factors such as smoking, sexually transmitted diseases (STD), history of miscarriages, and high maternal age are expected to fuel the growth of the market during the forecast period. Rise in ectopic pregnancies is also a significant factor which causes GTD. According to the National Center for Biotechnology Information (NCBI), the risk of ectopic pregnancy is 20 times higher in women who smoke. On the other hand, high risks of recurrence and complications that may occur after the therapy and treatment procedure may hinder the growth of the market during the forecast period.

The global gestational trophoblastic disease treatment market is currently dominated by many market players. The key players in the market are involved in new product launches and strategic partnerships to strengthen its market position. For instance, in September 2018, Novartis AG entered into a license and collaboration agreement with Cellular Biomedicine Group, Inc., a clinical stage biopharmaceutical company which develops therapies for cancer and degenerative diseases in Greater China.

Competitive Landscape:

• Teva Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals PLC
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Antares Pharma
• Mylan N.V.
• Novartis AG
• BP Pharmaceuticals Laboratories Company
• Fresenius Kabi AGAccord Healthcare, Inc.
• Eli Lilly and Company
• Sanofi
• Bayer AG
• Amgen Inc.
• Merck

Segmentation:The global gestational trophoblastic disease market has been segmented into type, treatment, and end user.

The market, on the basis of type, has been segmented into a hydatidiform mole, choriocarcinoma, placental-site trophoblastic tumor, epithelioid trophoblastic tumor, and others.

The market, based on the hydatidiform mole, has been further segmented into a complete, partial and invasive mole. The market, based on hydatidiform mole is expected to hold the largest share as it is the most common form of the gestational trophoblastic disease,  whereas choriocarcinoma is projected to be the fastest-growing market as the incidence rate of this form is increasing steadily according to a journal published by National Center for Biotechnology Information.

The market, by treatment, has been segmented into surgery, chemotherapy, suction dilation and curettage (D&C), and radiation therapy.

The market, based on surgery, has been sub-segmented into an abdominal hysterectomy and vaginal hysterectomy.

The market, by end user, has been segmented into hospital and clinics, diagnostic centers, and others.

The market has been segmented regionally into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The gestational trophoblastic disease market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The European gestational trophoblastic disease market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.

The gestational trophoblastic disease market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The gestational trophoblastic disease market in the Middle East & Africa has been segmented into the Middle East and Africa.

Regional Market Summary

Geographically, the Americas is projected to dominate the global gestational trophoblastic disease market owing to an increased awareness about the disease and favorable reimbursement scenario. Also, the rise in a number of marketing approvals, as well as product approvals in the field of oncology drive the market growth.

Europe is expected to hold the second largest position in the global gestational trophoblastic disease market. The market growth in this region is attributed to the availability of funds for research and an increasing healthcare expenditure.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the presence of a huge patient population and continuously developing economies.

On the other hand, the Middle East and Africa has the least share of the market. This is due to the stringent government regulations and lack of technical expertise in the treatment of the disease.

Latest Study Offers Detailed Insights On Male Breast Cancer Market 2019

Market Scenario:

Although breast cancer is common in women, even men suffer from the same. Men also have breast tissues and cancer starts when these tissues start to grow out of control. The breast ducts and glands present in men are not functional, but cancer in these areas can spread when cancer cells enter the blood or lymph system and are carried in the whole body. Men who have suffered from cancer before and undergone radiation therapy are at a high risk of suffering from male breast cancer.

The rising geriatric population and an increasingly obese population resulting in high levels of estrogen in males are expected to drive the growth of the market during the forecast period. According to an article published by the National Cancer Institute in April 2018, most of the men who suffer from breast cancer are 60 to 70 years old. Additionally, the rising healthcare expenditure is likely to boost the market growth. On the other hand, lack of knowledge of the disease and high cost of treatment may hinder the growth of the market during the forecast period.

The global male breast cancer treatment market is expected to grow slowly at a CAGR of ~ 3.6% during the forecast period from 2018 to 2023. Male breast cancer is caused when the breast tissues of males start growing out of control and become cancerous.

Numerous factors such as increasing obese population and growing geriatric population are expected to drive the growth of the market. For instance, in July 2017, the Bristol-Myers Squibb Company announced a broad clinical collaboration with Clovis Oncology for evaluating the combination of cancer drugs Nivolumab and Rucaparib in Phase 2 and Phase 3 clinical trials in multiple tumor types.

Moreover, favorable healthcare expenditures boost the growth of the market. However, lack of knowledge and the high cost of treatments may hamper the market growth during the assessment period.

Key players

Achieve Life Sciences, Inc., Pfizer, Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche, Sanofi, Novartis AG, BioNumerik Pharmaceuticals Inc., Seattle Genetics, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., AstraZeneca, Accord Healthcare, and Bayer AG are some of the key players in the global male breast cancer market.

Segmentation

The global male breast cancer market has been segmented into type, diagnosis, and treatment.

The market, on the basis of type, has been segmented into, ductal carcinoma in situ, Paget’s disease of the nipple, inflammatory breast cancer, and infiltrating ductal carcinoma.

The market, by diagnosis, has been segmented into, mammography, biopsy, PET scan, CT scan, MRI scan, and other tests. On the basis of diagnosis, biopsy is anticipated to record the largest growth owing to its accuracy of diagnosing the disease. It is also expected to be the fastest growing segment.

By diagnosis, biopsy is further segmented into, fine needle aspiration biopsy, core biopsy, and excisional biopsy.

The market, by treatment, has been segmented into, local treatments and systemic treatments.

By treatment, local treatments are further segment into, surgery and radiation therapy.

Surgery is further segmented into, mastectomy, breast-conserving surgery, and lymph nodes biopsy.

By treatment, systemic treatments are further segmented into, chemotherapy, hormone therapy, and targeted therapy.

Hormone therapy is further segmented into, using drugs and orchiectomy (castration).

Chemotherapy is further segmented into, adjuvant therapy and neoadjuvant therapy.

Targeted therapy is further segmented into, for HER2 positive breast cancer, for hormone receptor-positive breast cancer, and for cancer with BRCA mutations.

The European male breast cancer market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The male breast cancer market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The male breast cancer market in the Middle East and Africa has been segmented into the Middle East and Africa.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The male breast cancer market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

Regional Market Summary

Geographically, the Americas is anticipated to dominate the global male breast cancer market owing to the changing lifestyle and rising prevalence of breast cancer. According to an article published by, the American Cancer Society in April 2018, the lifetime risk of getting breast cancer in men is approximately 1 in 833. Europe is expected to hold the second largest position in the global male breast cancer market. The market growth in this region is attributed to the growing prevalence of rare cancers, the availability of funds for research, and increasing healthcare expenditure. According to the Cancer Research UK, 371 new cases of male breast cancer were reported in 2015 in the UK.

Asia-Pacific is anticipated to be the fastest growing region in the market due to the rising awareness regarding early symptoms of cancer and government support for healthcare facilities. According to a study published by the European Society for Medical Oncology in January 2016, there were 4.3 million new cases of cancer in China in 2015.

On the other hand, the Middle East and Africa has the least share of the market. Majority of the market of this region is expected to be held by the Middle Eastern region due to growing government initiatives for the healthcare sector.

Worldwide Pulmonary Atresia Diagnostics and Treatment Market 2019 Outlook, Top 10 Industry Players Comprehensive Analysis And Forecast To 2023

Pulmonary atresia is the type of inherited heart defect that a baby is born with. It arises when the pulmonary valve normally located between the right ventricle and the pulmonary artery doesn’t form properly. The valve should have three leaflets which allow the blood to flow forward into the pulmonary artery but prevent it from flowing backward into the right ventricle. In the case of congenital pulmonary atresia patients, the valve either malfunctions or does not form at all. The tissue formed in the place of pulmonary valve does not allow the blood flow into the pulmonary artery. This flaw develops in the first eight weeks of pregnancy and disturbs the flow of blood from the right ventricle to the pulmonary artery leading to the lungs. It can be recognized in a prenatal ultrasound.

The Global Pulmonary Atresia Diagnostics and Treatment Market Growth is expected to register a significant CAGR during the forecast period (2018–2023).

The most common symptoms are blue or gray-toned skin, troubled breathing, weakness, sleepiness, and others. Factors such as technological advancements, increasing awareness, lifestyle changes are the major driving factors for the growth of the market. However, unspecified regulatory issues, infection risks connected with surgical procedures, and ambiguous reimbursement policies are the factors limiting the market growth. Additionally, restrains for the market include the high cost of the surgical procedure and the risks involved in the procedures are likely to affect the pulmonary atresia diagnostics and treatment market negatively. 

Key Players

Some of the key players in the global pulmonary atresia diagnostics and treatment market are Kyowa Pharma Chemical Co. Ltd, AZAD partners, Abbott Laboratories, Dickinson and Company, Becton, C. R. Bard, Inc., B. Braun Melsungen AG, Medtronic plc., Teleflex Incorporated, JOHNSON & JOHNSON, Cook Group Incorporated, and Boston Scientific Corporation.

Segmentation

The global pulmonary atresia diagnostics and treatment market has been segmented on the basis of type, diagnosis, treatment and end users.

On the basis of treatment, the market has been classified as medication, cardiac catheterization, surgery. The cardiac catheterization is segmented into radiofrequency ablation and balloon valvotomy, balloon atrial septostomy, and stent placement. The surgery is segmented into right ventricular outflow reconstruction, blalock-taussig shunt, bi-directional glenn procedure, fontan procedure, and heart transplant.

On the basis of type, the market has been classified as pulmonary atresia with an intact ventricular septum and pulmonary atresia with ventricular septum defect.

On the basis of diagnosis, the market has been classified as pulse oximetry, electrocardiogram (ECG), echocardiogram (cardiac ultrasound), cardiac MRI and cardiac catheterization.

On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics, research institutes, and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

The European pulmonary atresia diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The pulmonary atresia diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The pulmonary atresia diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

The European market is expected to hold the second largest market share. Factors such as a rise in research expenses, advancement of technology, the decline in human health, and the necessity for innovative and effective therapies boost the growth of the market in this region. According to the Centers for Disease Control and Prevention, congenital heart defects are a foremost cause of birth defect associated with infant illness and deaths. The deaths often occur when the infant is less than 28 days old and hence diagnosis of the defect is utmost important.

In the pulmonary atresia diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, continuous development by companies operating into medical devices manufacturing. According to the Centers for Disease Control and Prevention, about 40,000 births are affected by congenital heart defects in the US every year.

Whereas the market share in Asia-Pacific region is also anticipated to experience growth in the near future due to access to optimal treatment facilities and growing demand for increasing government initiatives, advanced technology, better adoption rate, and rising healthcare expenditure.

The market in the Middle East & Africa is expected to account for the smallest share of the global pulmonary atresia diagnostics and treatment market due to an underdeveloped healthcare sector, the dearth of technical knowledge, and poor medical facilities.